Clinical trials for Polio

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Polio. For all clinical trials, go to clinical trials search

This list shows clinical trials for Polio

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Polio
Title Recruitment status Location
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules Not recruiting United Kingdom
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Not recruiting United Kingdom
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2 Not Recruiting United Kingdom
A study on the maternal and infant factors determining the performance of Rotavirus vaccines in African, Indian and European infants. Not Recruiting United Kingdom
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD’s dTpa-IPV vaccine (Repevax), when co-administered with GSK Biologicals’ MMR vaccine (Priorix) in 3 and 4-year-old healthy children. - DTPA-IPV (BOOSTRIX-IPV)-009 Authorised United Kingdom
A phase III open (partially double-blind), controlled, multicenter, multicountry primary & booster vaccination study to demonstrate the non-inferiority of the meningococcal serogroup C response of GlaxoSmithKline Biologicals’ Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ when given according to a 2, 3, 4 month schedule and immunogenicity of Hib-MenC when given as a booster dose at 12-15 months of age. - HIB-MENC-TT-012 HIB-MENC-TT-013 BST 012 Authorised United Kingdom
Whooping cough vaccination in pregnancy - assessment of immune responses in mothers and subsequent responses to infant vaccinations in their babies. Authorised United Kingdom
A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal serogroup C conjugate (Hib-MenC) vaccine given at 12-15 months of age to subjects who were primed in primary study 103974 (HIB-MENC-TT-012) and boosted in study 104056 (HIB-MENC-TT-013 BST:012). - Hib-MenC-TT-027, 028, 029 Authorised United Kingdom
Immunogenicity and safety of booster doses of the inactivated polio vaccine Recruiting Japan
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected Recruiting South Africa

Page last reviewed: 07/09/2015

Next review due: 01/09/2018